DRKS00031004
Recruiting
Phase 2
A Randomized Controlled Trial of Positive Psychology and Stress Management Interventions for Test Anxiety and Test-Related Stress
niversität Konstanz0 sites210 target enrollmentFebruary 16, 2023
Conditionstest anxiety and test related stress
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- test anxiety and test related stress
- Sponsor
- niversität Konstanz
- Enrollment
- 210
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Students who have at least two written exams remaining.
Exclusion Criteria
- •Severe depressive episodes, suicidality, participants currently undergoing psychotherapeutic treatment, participants taking medication.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentAlcoholic hepatitisMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2020-004534-38-DEDURECT Corporation300
Active, Not Recruiting
Phase 1
OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)IgA nephropathy (IgAN)Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2018-000075-33-ESOmeros Corporation434
Active, Not Recruiting
N/A
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseEUCTR2012-002806-31-HUKAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)500
Active, Not Recruiting
Phase 1
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)EUCTR2013-003713-18-ITMillennium Pharmaceuticals, Inc178
Active, Not Recruiting
N/A
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Symptoms and general pathology [C23]EUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500